Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Clinical Trial of CPI-613 Given Alone, or in Combination With Gemcitabine, in Patients With Metastatic Pancreatic Cancer

NCT01830322 is registered in ClinicalTrials.gov with Cornerstone Pharmaceuticals as lead sponsor.

NCT NCT01830322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01830322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Clinical Trial of CPI-613 Given Alone, or in Combination With Gemcitabine, in Patients With Metastatic Pancreatic Cancer
Lead sponsor
Cornerstone Pharmaceuticals
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2014
Completion date
December 31, 2018
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma